Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

Trial Profile

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms RIVA-F
  • Sponsors Bayer
  • Most Recent Events

    • 23 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 26 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top